MARKET

CHFS

CHFS

CHF Solutions
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.33
+0.08
+0.97%
After Hours: 8.16 -0.17 -2.04% 19:27 01/15 EST
OPEN
8.30
PREV CLOSE
8.25
HIGH
8.39
LOW
7.96
VOLUME
93.78K
TURNOVER
--
52 WEEK HIGH
38.70
52 WEEK LOW
5.80
MARKET CAP
22.79M
P/E (TTM)
-0.0993
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CHF Solutions Protects New Peripheral Vascular Access Catheter with Patent Application
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a peripheral vascular access catheter for use with its Aquadex(TM) system. The new dual lumen ultrafiltration catheter optimizes blood flow, prevents kinking, and is customizable for each patient, eliminating the need for multiple catheter sizes.
GlobeNewswire · 4d ago
CHF Solutions Protects New Peripheral Vascular Access Catheter with Patent Application
EDEN PRAIRIE, Minn., Jan. 12, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a peripheral vascular access catheter for use with its Aquadex™ system. The new dual lumen ultrafiltration catheter optimizes blood flow, prevents kinking, and is customizable for each patient, eliminating the need for multiple catheter sizes. Ultrafiltration with Aquadex provides clinicians with a simplified approach to gently remove excess fluid in patients with hypervolemia (fluid overload). A key advantage of the Aquadex system is its ability to provide venous access in the patient’s arm rather than the common and less comfortable central vein access. The addition of the innovative dual lumen catheter included in this patent helps to streamline processes for uninterrupted therapy, and may reduce inventory burden with the ability to customize a single catheter to any patient.“Blood flow optimization is an important element of effective ultrafiltration therapy and the catheter designs in this patent application will help elevate the precision clinicians have grown to love with Aquadex,” said John Erb, CEO of CHF Solutions. “We’re always looking for ways to improve each component of our therapy and consistently equip providers with the tools they need to provide the best care.”Aquadex SmartFlow is a simple, flexible and smart fluid management platform using ultrafiltration to stabilize patients experiencing fluid overload. It can be used by any bedside nurse trained on extracorporeal therapies and allows for up to a 4:1 patient to nurse ratio.About CHF Solutions CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the product inventions contained in this patent application. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.comMatt Bacso, CFA Gilmartin Group LLC Matt.bacso@gilmartinir.comMEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com
GlobeNewswire · 4d ago
CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a meta-analysis published in Heart Failure Reviews concludes that ultrafiltration (UF) increases fluid removal and weight loss and reduces rehospitalization and the risk of worsening heart failure in congestive patients, suggesting ultrafiltration as a safe and effective treatment option for volume-overload heart failure patients.
GlobeNewswire · 12/15/2020 13:00
CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF
GlobeNewswire · 12/15/2020 13:00
CHF Solutions Announces Webinar On Pediatric Ultrafiltration Therapy Hosted By Ladenburg Thalman & Co. On Dec. 8
EDEN PRAIRIE, Minn., Dec. 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (NASDAQ:CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that Ladenburg
Benzinga · 12/04/2020 13:05
CHF Solutions Announces Webinar on Pediatric Ultrafiltration Therapy hosted by Ladenburg Thalman & Co.
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that Ladenburg Thalman & Co. will host a conference call and webcast at 1:00p.m. Eastern Time on Tuesday, December 8, 2020 highlighting pediatric ultrafiltration therapy and the Aquadex SmartFlow(TM) System as part of Ladenburg Thalman's LT Healthcare Symposia Series.
GlobeNewswire · 12/04/2020 13:00
CHF Solutions Announces Webinar on Pediatric Ultrafiltration Therapy hosted by Ladenburg Thalman & Co.
EDEN PRAIRIE, Minn., Dec. 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that Ladenburg Thalman & Co. will host a conference call and webcast at 1:00p.m. Eastern Time on Tuesday, December 8, 2020 highlighting pediatric ultrafiltration therapy and the Aquadex SmartFlow™ System as part of Ladenburg Thalman’s LT Healthcare Symposia Series. Speakers include Dr. David Askenazi, M.D. MSPH, Director of the Pediatric and Infant Center for Acute Nephrology at Children’s of Alabama, University of Alabama-Birmingham, and Dr. Scott Sutherland, Pediatric Nephrologist at Lucile Packard Children’s Hospital and Clinical Professor of Pediatrics and Nephrology, Stanford University. Jeff Cohen, Managing Director, Equity Research at Ladenburg Thalmann & Co., will be moderating the discussion.To register for the conference call and webcast, please visit https://zoom.us/webinar/register/WN_aTBb91xqTmaa5-2ttrWn9g.About CHF Solutions CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the use of the Aquadex SmartFlow system to treat pediatric patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.comMatt Bacso, CFA Gilmartin Group LLC Matt.bacso@gilmartinir.com MEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com
GlobeNewswire · 12/04/2020 13:00
CHF Solutions Announces Webinar on Pediatric Ultrafiltration Therapy hosted by Ladenburg Thalman & Co.
GlobeNewswire · 12/04/2020 13:00
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHFS. Analyze the recent business situations of CHF Solutions through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHFS stock price target is 26.63 with a high estimate of 33.25 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 284.06K
% Owned: 10.38%
Shares Outstanding: 2.74M
TypeInstitutionsShares
Increased
2
15.17K
New
19
21.88K
Decreased
1
1.48K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.23%
Healthcare Equipment & Supplies
+0.12%
Key Executives
Chairman/Chief Executive Officer/Director
John Erb
President/Chief Operating Officer
Nestor Jaramillo
Chief Financial Officer
Claudia Drayton
Senior Vice President
Vitaliy Epshteyn
Lead Director/Independent Director
Warren Watson
Independent Director
Steven Brandt
Independent Director
Maria Costanzo
Independent Director
Jon Salveson
Independent Director
Gregory Waller
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CHFS
CHF Solutions, Inc. is a medical device company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex FlexFlow and the Aquadex SmartFlow systems are collectively called as Aquadex System. The Aquadex System is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System consists of: a console, a piece of capital equipment containing electromechanical pumps and an liquid crystal display (LCD) screen; a one-time disposable blood set, an integrated collection of tubing, filter, sensors, and connectors that contain and deliver the blood from and back to the patient; and a disposable catheter, a small, dual-lumen extended length catheter designed to access the peripheral venous system of the patient.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CHF Solutions Inc stock information, including NASDAQ:CHFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHFS stock methods without spending real money on the virtual paper trading platform.